Verdict94/ 100
Grade A · #1CoreAge Rx
The most honest middle of the market: nationwide access, both molecules at one flat, no-surprise price.
Visit CoreAge RxHead-to-head verdict
CoreAge Rx vs Kin Meds
Two GLP-1 providers, compared side by side on The Verdict Score — our published six-factor rubric. Same yardstick, and no score is adjusted for payment.
Published by The GLP-1 Verdict
Pricing sources checked: CoreAge Rx: August 2026 · Kin Meds: Check date not recorded
vs
Verdict69/ 100
Grade C · #192Kin Meds
Kin Meds is a LegitScript-verified telehealth platform offering both compounded GLP-1s (semaglutide from $199/mo, tirzepatide from $249/mo) and brand-name FDA-approved options including Wegovy injection and…
Visit Kin MedsThe verdict
Winner: CoreAge Rx
CoreAge Rx takes it with a higher Verdict Score — 94/100 to 69/100 (grade A vs C). Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch. Kin Meds still earns its place — shoppers who want compounded and brand-name GLP-1 plus a longevity stack on one platform.
The score compares published program terms and features; it does not measure clinical outcomes or predict which treatment will suit you.
Factor by factor
Both scored on the same six factors — see the methodology. The brass bar marks the stronger side on each.
92Real-world results75
92
Real-world results75
97Price honesty64
97
Price honesty64
96Prescriber access57
96
Prescriber access57
88Formulary choice90
88
Formulary choice90
95Cancellation fairness56
95
Cancellation fairness56
93Member support74
93
Member support74
Price, coverage & features
| Metric | CoreAge Rx | Kin Meds |
|---|---|---|
| Verdict Score | 94/100 | 69/100 |
| Grade | A | C |
| Semaglutide | $99/mo | From $149/mo (brand Wegovy) |
| Tirzepatide | $149/mo | From $149/mo (brand Zepbound) |
| Coverage | All 50 states | Not disclosed |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | No | No |
CoreAge Rx
What we like
- Flat, all-in monthly price with no intro-rate step-ups after month one
- Both compounded semaglutide and tirzepatide on one account
- Available in all 50 states
- Straightforward, low-friction cancellation
The caveats
- Not the cheapest — flat-price challengers like Trimi Health and Alan Meds undercut its sticker price
- No FDA-approved brand-name option (compounded only)
- Does not yet publicly name its 503A/B pharmacy partner
Kin Meds
What we like
- Publicly lists $199/mo compounded semaglutide and $249/mo compounded tirzepatide
- Brand-name options too — Wegovy injection and pill, Zepbound, Foundayo from $149/mo entry pricing
- LegitScript verified
- Clearly identifies itself as the intake platform and a licensed third-party pharmacy as the dispenser
- Broad longevity menu (Sermorelin, NAD+, Glutathione) plus TRT, hair, skin, and sexual health
The caveats
- Legal entity name and state of incorporation not publicly disclosed
- The third-party pharmacy partner isn't named, and Kin Meds isn't itself a licensed pharmacy
- Per-state availability not listed
- $149/mo brand pricing is the insured entry tier — cash-pay patients should expect higher real costs
- Lab work and dose-titration support not clearly described
Our pick — visit
Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch.
Visit CoreAge Rx Read the full CoreAge Rx review →Also worth a look
Shoppers who want compounded and brand-name GLP-1 plus a longevity stack on one platform.
Visit Kin Meds Read the full Kin Meds review →Keep comparing
Neither of these has to be the answer: the rivals we rank against CoreAge Rx cover the 7 programs closest to it, and the same shortlist for Kin Meds does the reverse.
More on CoreAge Rx
More on Kin Meds
Or browse the full comparison hub, every head-to-head A to Z and the complete rankings.
Pricing, states and verification reflect each provider's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.